Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

Project Oncology®

Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

1M ago

MP3•Pagina episodului

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 11, 2024 21:41 (3d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua E. Reuss, MD
The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.

160 episoade

#Oncology #Obstetrics And Gynecology #Oncology And Hematology #Omnia Education #Cme/ce #Oncology Power Hour #ReachMD #Women's Health #Women's Health Fridays™ #Science #Medicine #Health and Well-Being #Project Oncology®